Dr. Wrighton-Smith is our Chief Executive Officer and a Director. He has held both positions since founding Oxford Immunotec in 2002. Before founding Oxford Immunotec, Dr. Wrighton-Smith held senior positions with PowderJect Pharmaceuticals PLC, as director of strategic development, and managing director of PowderJect Diagnostics Ltd., a subsidiary of PowderJect engaged in the development of cellular immune-based diagnostics. Dr. Wrighton-Smith earned his master’s degree in Engineering, Economics and Management, and his doctorate in Medical Engineering from Oxford University.
Mr. Linn is our Chief Operating Officer, a position he has held since joining our company in August 2017. Before joining Oxford Immunotec, Mr. Linn served as a senior vice president for IMS Health Holdings, Inc. from 2010 to 2016. Before joining IMS Health, Mr. Linn was a director at TPG Capital, from 2008 to 2010, where he worked with healthcare and consumer portfolio companies to drive operating improvements. Prior to joining TPG Capital, Mr. Linn was a senior vice president at McKesson Corporation where he was responsible for marketing strategy, product development and customer programs. While with McKesson, Mr. Linn served as President of Health Mart, its franchise pharmacy business, and oversaw McKesson’s consumer products division, packaging business RxPack, and the McKesson Patient Relationship Solutions division. Earlier in his career, Mr. Linn was a vice president at Merck-Medco Managed Care, LLC and worked for McKinsey & Company. Mr. Linn earned his bachelor’s degree in Economics from the University of Dallas and his Master of Business Administration from the University of California at Berkeley.
Mr. Altieri is our Chief Financial Officer, a position he has held since joining our company in 2012. Before joining Oxford Immunotec, from 2007 through 2011, Mr. Altieri was vice president and chief financial officer of Salient Surgical Technologies, Inc., a medical technology company that developed and marketed surgical advanced energy products. From 2004 to 2007, Mr. Altieri was senior vice president of finance and chief financial officer of Straumann USA, a global leader in the field of implant dentistry and dental tissue regeneration. Earlier in his career, beginning in 1992, Mr. Altieri was vice president and chief financial officer of Mitek Surgical Products, Inc., which was acquired by Johnson & Johnson in 1995. Following the acquisition, Mr. Altieri continued to oversee the financial operations of DePuy Mitek as vice president – finance through 2004. Mr. Altieri earned his bachelor’s degree in Accounting from Northeastern University and his Master of Business Administration from Babson College.
Mr. Schroeder has been our Chief Commercial Officer since 2013. Prior to becoming our Chief Commercial Officer, Mr. Schroeder served as our President, North America from 2007 to 2013, overseeing sales and marketing operations in the United States. Before joining Oxford Immunotec, from 2002 to 2007, he served as vice president of sales, breast health and vice president of marketing at Cytyc Corporation, which manufactured and sold tests used in the diagnosis of cervical cancer and other women's health-related illnesses and merged with Hologic Corporation in 2007. Before working at Cytyc, from 2000 to 2002, Mr. Schroeder was vice president, sales and marketing for CytoLogix Corporation, a cellular diagnostics company. Earlier in his career, from 1984 to 2000, Mr. Schroeder held various sales positions with increasing levels of responsibility for the diagnostics division of Abbott Laboratories, ultimately becoming director of worldwide marketing for the division. Mr. Schroeder earned his bachelor’s degree from Southeast Missouri State University.
Dr. Wenstrup is our Chief Medical Officer, a position he has held since joining our company in July 2017. Before joining Oxford Immunotec, Dr. Wenstrup spent over a decade at Myriad Genetics, Inc., where he served as executive vice president and chief medical officer from 2015 through July 2017, and chief medical officer, Myriad Genetic Laboratories, Inc., from 2006 through 2015. In addition to building and leading Myriad's clinical and medical affairs teams, Dr. Wenstrup was actively involved in the company's product development, M&A, and in-licensing activities. Prior to joining Myriad Genetics, Dr. Wenstrup served as a tenured professor of pediatrics (human genetics) at Cincinnati Children's Hospital Medical Center and as a tenured professor of biomedical engineering at the University of Cincinnati. He was also the founding director of the Molecular Diagnostics Laboratory at Cincinnati Children's Hospital and co-founder of Assurex Health, Inc., now a subsidiary of Myriad Genetics, Inc. Dr. Wenstrup earned his medical degree from the University of Cincinnati College of Medicine and completed a pediatrics residency at the University of Minnesota Hospital and a fellowship in medical genetics at the University of Washington.
Dr. Edwardson has been our Senior Vice President, Head of Blood Screening since August 2017. Prior to this appointment, he had served as our Chief Operations Officer since 2013, overseeing our operations worldwide, including all manufacturing, research and development activities, quality assurance and regulatory affairs and laboratory operations. Dr. Edwardson joined Oxford Immunotec in 2008 and prior to becoming Chief Operations Officer, he served as General Manager of our operations in the United Kingdom. Before joining Oxford Immunotec, from 2003 to 2008, Dr. Edwardson was vice president of medical technologies for Prometic Biosciences Ltd., a subsidiary of Prometic Life Sciences Inc., which designed, developed, manufactured and commercialized affinity adsorbents sold to biopharmaceutical companies for use in their drug manufacturing processes. From 1999 to 2003, he served as technical director at Tayside Flow Technologies and Tissuemed Ltd, two start-up companies focused on development and commercialization of implantable devices. Dr. Edwardson earned his bachelor’s degree in Biochemistry and Physiology from Leeds University and his doctorate from Cambridge University.
Ms. Keiley has been our Senior Vice President, General Counsel since March 2017. From January 2015 to March 2017, she held the position of Vice President, General Counsel, where she also had responsibility for all of our legal affairs. Ms. Keiley joined our company in September 2012 and served as Associate General Counsel until her promotion in January 2015 to Vice President, General Counsel. Before joining Oxford Immunotec, from July 2008 to March 2012, Ms. Keiley was assistant general counsel, Americas of Zimmer, Inc., a subsidiary of Zimmer Holdings, Inc., the world’s largest pure-play orthopedic device manufacturer. Prior to working at Zimmer, Ms. Keiley was a trial lawyer and partner with Wildman, Harrold, Allen & Dixon in Chicago, Illinois where she represented clients in a wide variety of commercial disputes and transactions. Ms. Keiley earned her bachelor’s degree in Psychology/Philosophy from Boston College and her juris doctor from Loyola University School of Law.
Mr. Gansler is our Senior Vice President, Global Head of Human Resources, a position he has held since joining our company in 2015. Before joining Oxford Immunotec, Mr. Gansler was senior vice president, human resources, for Millennium Pharmaceuticals, now Millennium: The Takeda Oncology Company, where he played a key leadership role, implementing employee engagement and integrated talent management programs which contributed to Millennium's consistent ranking during his tenure as one of the best places to work in the United States. Prior to Millennium, Mr. Gansler spent more than twenty years with Johnson & Johnson, holding a variety of roles of increasing responsibility, including worldwide vice president, human resources. During his tenure with J&J, he led the human resources function for four separate business units and managed several post-acquisition integrations. He also designed innovative compensation programs and implemented fundamental changes to leadership development and succession planning for J&J's 80,000 employees. Mr. Gansler earned his bachelor’s degree in Industrial Administration from the General Motors Institute and his Master of Business Administration-Finance and juris doctor from Seton Hall University.